AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05161117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online fall prevention education module
Description: Participants in both intervention and control groups will complete a 20 minute online module: Management of the Patient at Risk for Falls, through the MyLearning education platform. Most caregivers would have taken this module during competencies or orientation, but at various times. It will be taken by all participants in this study to serve as a baseline understanding of identifying and caring for patients at risk for falls. Participants will be enrolled in the module by a member of the research team, and learner transcripts will available through MyLearning education to confirm completion.
Study NCT06100029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lavender
Description: The lavender aroma (L. angustifolia ssp. Angustifolia) is provided by Pranarom International, Ghislenghien, Belgium. Lavender aroma will be contained in a 10 ml glass bottle with a drop stopper and place the bottle within 20 cm of the patient's pillow so that the aroma can reach the patient. The entire course of treatment lasts 5 days.
Study NCT06100029 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: A2F bundle
Description: A: assess, prevent, and manage pain; B: both spontaneous awakening and breathing trials; C: choice of analgesia and sedation; D: delirium assessment, prevention, and management; E: early mobility and exercise; and F: family engagement/empowerment
Study NCT05336968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide-Ketorolac-Ropivacaine
Description: Experimental for Osteoarthrosis of the Knee. One randomized injection to intraarticularly into affected knee at time of randomization
Study NCT05336968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide-Ketorolac-Ropivacaine
Description: Experimental for Osteoarthrosis of the Knee. One randomized injection to intraarticularly into affected knee at time of randomization
Study NCT05709249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XLJDOD compound granule
Description: Treatment will begin within 3 months after standard adjuvant chemotherapy and compliance will be continuously monitored. XLJDOD will be taken twice a day, infused with warm water, 1 hour after lunch and dinner. One course of treatment will take 28 days in 1 month, and 2- to 3-day rest. Treatment will continue for 6 courses.
Study NCT06100029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A2F bundle
Description: A: assess, prevent, and manage pain; B: both spontaneous awakening and breathing trials; C: choice of analgesia and sedation; D: delirium assessment, prevention, and management; E: early mobility and exercise; and F: family engagement/empowerment
Study NCT06087068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyroxine
Description: The treatment goal after lobectomy was to control TSH within the normal reference range (0.4-5 mU/L)
Study NCT05709249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (XLJDOD mimetic agent)
Description: The course of placebo in control group will be in accordance with that of XLJDOD in intervention group.
Study NCT05606718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: dapagliflozin 10mg once daily for 3 months after randomization
Study NCT06034704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plantar fascia self massage with a magnetic fascia ball
Description: Participants were asked to roll the magnetic fascia ball on the sole of each foot for 3 minutes each, from the metatarsal heads towards the heel, concentrating on the medial longitudinal arch. Participants were informed that more intense pressure would be more beneficial and were asked to apply pressure in a way that would not cause pain.
Study NCT06034704 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plantar fascia self massage with a non-magnetic fascia ball
Description: Participants were asked to roll the non-magnetic fascia ball on the sole of each foot for 3 minutes each, from the metatarsal heads towards the heel, concentrating on the medial longitudinal arch. Participants were informed that more intense pressure would be more beneficial and were asked to apply pressure in a way that would not cause pain.
Study NCT05606718 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: guideline-directed medical therapy (GDMT)
Description: guideline-directed medical therapy (GDMT)
Study NCT05606718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: guideline-directed medical therapy (GDMT)
Description: guideline-directed medical therapy (GDMT)
Study NCT05745038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SONATA
Description: The SONATA intervention is composed of five components, network diagnostics, network engagement, opportunity creation, skill building and goal-setting, and feedback, that will be audio-recorded and held over six scheduled sessions.
Study NCT05650190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel spectacle lens design
Description: Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia
Study NCT05650190 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spectacle lenses
Description: Single vision, impact resistant spectacle lenses
Study NCT04771897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). During Part 1, BXQ-350 will be administered by intravenous (IV) infusion over twelve months.
Study NCT04771897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). During Part 2, BXQ-350 will be administered by intravenous (IV) infusion over twelve months.
Study NCT06008353 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
Study NCT05274659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KJ103
Description: Recombinant Immunoglobulin G Cleaving Enzyme
Study NCT05274659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06417073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-To-Face Task-orianted Training
Description: In this study, face-to-face task-oriented station training is provided by trained occupational therapists to elderly nursing home residents. Each session involves structured activities that simulate real-world challenges designed to improve cognitive and hand functions. These include exercises to enhance fine motor skills, hand strength, coordination, and cognitive tasks such as problem-solving and memory exercises.
Study NCT06417073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Rehabilitation Task-orianted Training
Description: This intervention utilizes video-conferencing technology to deliver task-oriented training to elderly nursing home residents, focusing on cognitive and hand function improvements.
Study NCT06417073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Task-orianted Training
Description: Home-Based Task-Oriented Training Intervention Description:~This home-based intervention involves a series of task-oriented activities specifically designed to improve cognitive and hand functions for elderly residents in nursing homes. Participants carry out prescribed activities independently, based on detailed guides provided by occupational therapists. The activities are tailored to stimulate cognitive processes and enhance fine motor skills, including tasks like sorting, assembling, and manipulative exercises that replicate daily challenges. Each participant follows a structured program of daily 45-minute sessions for two weeks, with periodic remote check-ins by therapists to assess progress and adjust the difficulty of tasks as needed. This format allows participants to engage in rehabilitation at their own pace, within the comfort of their own living spaces, fostering greater autonomy and adherence to the intervention.
Study NCT04875819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine
Description: One dose (0.5 ml) of conjugate vaccine against meningococcal serogroups ACWY (Menveo®) and one dose of a recombinant protein-based vaccine against meningococcal serogroup B (Bexsero®) at day 0 followed by another dose (0.5 ml) of each vaccine at day 60.
Study NCT04875819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine
Description: One dose (0.5 ml) of pneumococcal conjugate vaccine (Prevenar13®) at day 0 and one dose (0.5 ml) of pneumococcal polysaccharide vaccine (Pneumovax23®) at day 60.
Study NCT06180382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Administration of adalimumab with optimisation either 80 mg every 14 days by subcutaneous injection, or the same dose of 40 mg every 7 days.
Study NCT06180382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Strategy B: administration of vedolizumab 300mg by infusion at baseline, 14 days, 42 days and 60 days, followed by a dose of 108mg every fortnight by subcutaneous injection.
Study NCT05946395 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing aid
Description: Fitting a hearing aid
Study NCT05946395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aid
Description: Fitting a hearing aid
Study NCT05147987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hands free wearable breast pump
Description: Use of a supplementary breast pump which can be discreetly worn and is hands free
Study NCT05946395 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speech therapy session
Description: As speech therapy is part of standard care, the objective of the study will be to compare the impact of synchronous or delayed audioprosthetic and speech therapy care on the impact of deafness in elderly patients.
Study NCT06197880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anterior teeth retraction
Description: En masse retraction of the upper and lower anterior segments using maximum anchorage
Study NCT04958187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG-3777
Description: Arm assigned to this intervention will receive 2 mg/kg, IV
Study NCT01714089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60 125 ml
Study NCT01714089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60 250 ml
Study NCT01714089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta 1a
Study NCT05946395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech therapy session
Description: As speech therapy is part of standard care, the objective of the study will be to compare the impact of synchronous or delayed audioprosthetic and speech therapy care on the impact of deafness in elderly patients.
Study NCT05903131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine behavioral weight intervention
Description: Weekly telephone calls during the first month, biweekly during the next 5 months, and then monthly for the last 7 months (12 months total). Each telephone session will be 30 minutes long.
Study NCT05903131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progestin
Description: Released via the levonorgestrel-releasing IUD.
Study NCT05903131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: 1-3 page handouts
Study NCT05903131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing IUD.
Description: Standard of care
Study NCT05903131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel-releasing IUD.
Description: Standard of care
Study NCT05029856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII B.1.351
Description: Intramuscular (deltoid) injections of 3 μg SII B.1.351 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21.
Study NCT05029856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII B.1.351
Description: Intramuscular (deltoid) injections of 5 μg SII B.1.351 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21.
Study NCT05029856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII Bivalent
Description: Intramuscular (deltoid) injections of 6 μg SII Bivalent and 50 μg Matrix-M1 Adjuvant, 2 doses: 1 on Day 0 and 1 on Day 21.
Study NCT05029856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII Bivalent
Description: Intramuscular (deltoid) injections of 10 μg SII Bivalent and 50 μg Matrix-M1 Adjuvant, 2 doses: 1 on Day 0 and 1 on Day 21.
Study NCT05029856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII B.1.617.2
Description: Intramuscular (deltoid) injections of 5 μg SII B.1.617.2 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21.
Study NCT06089187 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endotracheal intubation using an endotracheal tube with cuff inflated with air
Description: After endotracheal intubation, the endotracheal tube cuff is inflated with air
Study NCT06089187 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation using an endotracheal tube with cuff inflated with saline
Description: After endotracheal intubation, the endotracheal tube cuff is inflated with saline
Study NCT06640933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.
Study NCT05866211 — intervention group
Intervention type: OTHER
Intervention: Previous exposure to SARS-CoV-2
Description: This is an observational study in which no intervention will be applied.
Study NCT06191315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Study NCT06191315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Study NCT04951648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: Almonertinib 165 mg，orally once a day Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
Study NCT04951648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Pemetrexed (500mg/m2) plus Carboplatin (AUC5)or Pemetrexed (500mg/m2) plus Cisplatin (75mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4\~6 cycles, followed by pemetrexed mainten-ance therapy every 3 weeks until disease progress-ssion, unacceptable toxicity or other discontinuation criteria are met.
Study NCT04902482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCycle Mark 3
Description: The iCycle Mark 3 is a cycle ergometer, designed to be used by people with SCI while they are seated in their own wheelchairs. The purpose of iCycle is to stimulate the leg muscles in the correct phase for cycling while motivating the person with a Virtual Reality cycling event, perhaps a race, to try to use their muscles.
Study NCT05395143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Description: Zinc sulfate tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
Study NCT05395143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
Study NCT06366165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: seemingly irrelevant funny videos and memes in teaching
Description: linking funny videos and memes to special care dentistry curriculum lectures
Study NCT06065774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Laterally Closed Tunnel Technique with SCTG
Description: Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~Then specially designed tunneling instruments \[devmed\] were used through the sulcular incision to create a pouch.~A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~SCTG was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene.
Study NCT06085638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given by SC (under the skin) or IV (vein)
Study NCT06085638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Description: Given by PO
Study NCT05024045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-338
Description: Oral
Study NCT05024045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Oral
Study NCT05805371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
Description: Given IV
Study NCT05805371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT05805371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood, stool, and urine sample collection
Study NCT05805371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT05805371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05805371 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo radiation
Study NCT05805371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis
Study NCT05805371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphodepletion Therapy
Description: Undergo lymphodepletion
Study NCT06085638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO~TAMIBAROTENE Azacitidine Azacitidine, 5-azacytidine, 5-aza, Vidaza™, 5-AZC, AZA-CR, Ladakamycin, NSC-102816, Azacytidine Venetoclax ABT-199, GDC-0199, Venetoclax
Study NCT06650098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: artificial intelligence-supported mobile application
Description: It is aimed that an artificial intelligence-based mobile application that includes information, nutrition, exercise programs, complications and medication tracking, personalized suggestions, alarms and reminders, which will enable diabetic individuals to follow their glucose targets, support patients in their diabetes education, awareness and disease management to continue more actively. In addition, it is aimed that patients can easily access information, prevent acute and chronic complications, present physical activity and nutrition suggestions in accordance with the person\&#39;s lifestyle, follow up on medications with alarms and reminders, prevent the negative results of complications in advance, and improve individuals\&#39; diabetes-specific knowledge levels, compliance with treatment, self-management and care with information and guidance about foot care to reduce the risk of diabetic feet, which is particularly risky for diabetic patients.
Study NCT06650098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WEB based application
Description: The content plan for the web-based mobile application group will be prepared with technical support as specified. Patients will be able to log in to the mobile application with a username and password that will be defined specifically for them. Patients will be informed about how the website is used during the first meeting. They will be able to access all the information they need about diabetes with the web-based mobile application. Statistical data such as the frequency of individuals visiting the site, which sections they use more often and how much time they spend will be calculated.